SignalMacro

PROSPECTIVE GRANT OF AN EXCLUSIVE PATENT LICENSE: DEVELOPMENT AND COMMERCIALIZATION OF MIFEPRISTONE AND ANALOGUES TO TREAT HYPERCORTISOLISM-RELATED INSULIN RESISTANCE DISORDERS - FEDERALREGISTER

Patent license exclusivity signals commercial catalyst for mifepristone analogues in metabolic disorders.

What changed

Patent license exclusivity signals commercial catalyst for mifepristone analogues in metabolic disorders.

Why it matters

Patent license exclusivity signals commercial catalyst for mifepristone analogues in metabolic disorders. — impact context not separately stored; see What changed.

Sources

federalregister